Complaining about a smallcap biotech for the posibility of needing to raise capital at some point in the future and 'speculative being a good description' is sort of stating the obvious isn't it? Speculative is indeed what a small company without revenue is.. It sounds like some of these posters may be better off putting their money into an ETF or a nice set of multi billion $ blue chips.
